VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis

CX3CR1 has been identified as a highly attractive target for several therapeutic interventions. Despite this potential, no potent antagonists, either small molecule or monoclonal antibody, have been identified. Here we describe the lead finding and engineering approach that lead to the identificatio...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Sarah Low, Haixia Wu, Kavita Jerath, Annette Tibolla, Birgit Fogal, Rebecca Conrad, Deborah Webb, Margit MacDougall, Steven Kerr, Valentina Berger, Rajvee Dave, Jorge Villalona, Lynn Pantages, Jennifer Ahlberg, Hua Li, Diane Van Hoorick, Cedric Ververken, John Broadwater, Alisa Waterman, Sanjaya Singh, Rachel Kroe-Barrett
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis Group 2020-01-01
Serija:mAbs
Teme:
VHH Antibodies
GPCR
atherosclerosis
BI 655088
biophysical assessment
pharmacokinetic profile
Online pristup:https://www.tandfonline.com/doi/10.1080/19420862.2019.1709322
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items